The FDA probably won't approve the Novartis painkiller Prexige now that it's faced regulatory action in other countries, according to CEO Daniel Vasella. Report
The FDA probably won't approve the Novartis painkiller Prexige now that it's faced regulatory action in other countries, according to CEO Daniel Vasella. Report